INTRODUCTION
Allo-SCT is a treatment option for a number of malignant and nonmalignant lympho-hematopoietic diseases. Although it may be curative in diseases with high risk of fatal outcome, it is associated with significant morbidity and mortality. Specifically, acute and chronic GVHD (cGVHD) is a major cause of morbidity and nonrelapse mortality, limiting the success of allo-SCT. 1 cGVHD occurs almost exclusively before 3 years post transplant and may affect various organs, such as skin, mucosa, liver, gastrointestinal tract or lungs. In addition, it may have various manifestations, such as scleroderma-like symptoms, sicca-syndrome, immune-mediated cytopenias and chronic immunodeficiency. It may develop in between 20-85% of SCT recipients, 2 and the incidence depends on several factors, including stem cell source, donor type and age. 3 Late onset non-infectious pulmonary complications are observed in up to 23% of the patients after allo-SCT, 4 and some of these may be due to cGVHD. The classical pulmonary manifestation of cGVHD is bronchiolitis obliterans syndrome (BOS), but organizing pneumonia or nonspecific fibrosis may be observed. In 2005, a Consensus Conference on Clinical Practice in cGVHD issued a suggestion for a definition, 1 comprising spirometric criteria of airway obstruction, radiological criteria of bronchiolitis and absence of infection, and if feasible a histological verification.
The prevalence of BOS is estimated to be 2-5% among all allo-SCT recipients and up to 6-14% among long-term survivors who develop cGVHD. 4, 5 Although alternative treatments such as azithromycin, montelukast, imatinib and extracorporeal photopheresis may in some cases reverse or halt the progressive decline in lung function in cGVHD/BOS, the response to pharmacological therapy is uncertain and often disappointing and results have not improved over the past 20 years. [6] [7] [8] [9] Lung transplantation (LTx) could be a therapeutic option for selected patients developing severe lung dysfunction in the course of cGVHD/BOS, and several case reports have been published. [10] [11] [12] [13] According to the registry of the International Society of Heart and Lung Transplantation (ISHLT), in the period from 1995 to 2010, 1% of all LTx were performed due to obliterative bronchiolitis (retransplants excluded), 14 but the proportion of these that have previously had a hematopoietic SCT is not registered (Edwards L, ISHLT, personal communication).
In a questionnaire survey to 107 European Group of Blood and Marrow Transplantation centers, a total of 47 solid organ transplantations in 40 patients after allo-SCT were reported. 15 Among these were 12 lung transplants. Notably, within the median observation time of 23 months after LTx in that study, four patients died. These data were not related to survival in comparable patients receiving LTx for other reasons. In summary, it remains unclear whether patients with cGVHD/BOS profit from LTx and whether the long-term results are good enough in these patients to justify priority compared with other LTx candidates given the prevailing scarcity of suitable organs.
The aim of this study is to assess the total number of LTx performed in patients with a history of allo-SCT and cGVHD in the Nordic countries, to characterize the selection criteria, and to compare the results achieved in these patients to the results in comparable patients among the general population of lung recipients.
MATERIALS AND METHODS

Data collection
In the Nordic countries (Sweden, Denmark, Norway and Finland), all allo-SCT and LTx are performed at institutions of the public health care service, which covers the entire population in the countries. Data on allo-SCT in these countries were obtained from the European Group for Blood and Marrow Transplantation (EBMT). All LTx in these countries are performed at centers where the recipients are controlled at least once a year after transplantation. Information of all LTx recipients is routinely collected in the medical files and local databases from which we have retrieved all patients with a history of allo-SCT and cGVHD. Also, as background information for comparison, data on all LTx performed in the Nordic countries was obtained from Scandiatransplant (www.scandiatransplant.org). As it is known that young age favorably predicts outcome after LTx, and that long-term results after LTx are better in bilateral LTx (BLTx) than single LTx, and that survival has improved over the years, 14 the allo-SCT patients who received LTx were compared with a control group matched for age, BLTx and year of LTx. Although Iceland participates in the Scandiatransplant cooperation and geographically belongs to the Nordic region, there is no LTx program on Iceland, and data from this country have therefore not been included in this study.
Statistical analysis
Data are presented as number (n), median, range and percent as appropriate. Survival analyses were performed using Log Rank Mantel-Cox test and Graph Pad Prism 5.0 software (Graph Pad Software, La Jolla, CA, USA). A value of Po0.05 was regarded statistically significant.
RESULTS
The total number of allo-SCT registered in the four Nordic countries by 2011 was 4798 and the total number of LTx was 1544, and the increased activity in the decade from 2000 to 2010 is shown in Table 1 . The total registered number of LTx performed in patients with cGVHD related BOS after allo-SCT by 1 March 2012 was 13. Data on each individual patient are shown in Table 2 . In these patients, the allo-SCT was performed in the period from 1983 to 2010, and the indications were AML (n ¼ 6), CML (n ¼ 3), ALL (n ¼ 2), immunodeficiency (n ¼ 1) and aplastic anemia (n ¼ 1). Median age at allo-SCT was 24 years (7-41 years). The LTx in these patients were performed from 1997 to 2012, in which period the total number of LTx was 1301. The median age at LTx was 34 years (16-55) and there was a median interval between allo-SCT and LTx of 8.2 years (0.6-16 years). Before LTx, all patients had respiratory failure and a forced expiratory volume in 1 s/forced vital capacity ratio o0.7 and forced expiratory volume in 1 s o75% of predicted (see Table 2 ), radiological evidence of bronchiolitis and no current respiratory tract infection. All patients except two (no. 5 and 10 in Table 2 ) received longterm oxygen treatment for respiratory insufficiency. Extrathoracic manifestations of cGVHD, the immunosuppression given at the time of listing for LTx and other information relevant for the selection for LTx are shown in Table 2 . Bronchoscopic samples before LTx had shown colonization with Pseudomonas aeruginosa in patient no. 5 and Stenotrophomonas maltophilia in patient no. 6 and (Table 2) , no other patient had demonstrable microbial colonization. Patient no. 6 was in need of a wheelchair, but was considered to have rehabilitation potential as required for LTx. 16 Notably, patient no. 11 was critically ill, was treated with high doses of steroids and had a percutaneous endoscopic gastrostomy because of severe malnutrition. All patients received BLTx, and the median observation time after LTx was 4.2 years (0.1-15). The perioperative course was unremarkable in all but patient no. 11 (Table 2 , see below). Immunosuppression after LTx was given according to local standard protocols. Thus, seven patients were given induction therapy with anti-thymocyte globulin, one with dacluzimab and five patients received no induction therapy. All patients received mycophenolate mofetil and prednisolone, seven patients were given CsA, while six patients were given tacrolimus as rejection prophylaxis.
All patients were considered to have cGVHD/BOS. Confirming this, pathological examination of the extirpated lungs showed obliterative bronchiolitis in 12 patients, while one showed nonspecific fibrosis (patient no. 12 in Table 2 ).
Complications of LTx All patients were routinely followed with surveillance bronchoscopies and transbronchial biopsies after LTx. The number of acute rejections is noted in Table 2 , and did not differ from other LTx patients. According to standard protocols, the CMV status was monitored regularly after LTx. Three patients had CMV infection, of which one was considered a primary infection. Four patients developed BOS, of which one was successfully retransplanted 3.5 years after the primary LTx. The total mortality was 2/13 (15%), 1 year survival 90%, 3 year survival 78% and 5 year survival 75% (Figure 1) . Of the two patients that died, one died of relapsing AML, 25 months after allo-SCT and 13 months after LTx, which was performed in remission. The relapse occurred 4 weeks after treatment of acute lung allograft rejection with high-dose corticosteroids. Notably, a relapse of the primary hematological malignancy was seen only in this single recipient. The other patient died of assumed septicemia with undetermined causative agent 2 months after LTx and 10 years after allo-SCT. Finally, by searching the Scandiatransplant registry we found that 294 patients in the same age group received BLTx in the same period in the Nordic countries. Compared with this control group, we found that survival did not seem to be inferior in the 13 patients lung transplanted after allo-SCT within the observation period, although it should be noted that the comparison has low statistical power (P ¼ 0.45, see Figure 1) . Notably, using a log-rank comparison, we found that the survival in the control group was better than the survival of all LTx patients in this period (P ¼ 0.001), indicating that the lung transplanted allo-SCT-patients were selected from a group with better prognosis after LTx (Figure 1 ).
DISCUSSION
Allo-SCT is an increasingly used treatment for several hematological diseases, and the number of allo-SCT performed in the Nordic countries is currently about 22.5 per million inhabitants per year. Some patients develop cGVHD and respiratory failure due to BOS after allo-SCT, and in our countries, a total of 13 patients have been treated with LTx due to cGVHD/BOS after allo-SCT.
As both allo-SCT and LTx are provided exclusively by the public health-care services in our countries and the entire population has free access to health-care services including allo-SCT and LTx, and as data on all LTx are available at the transplant centers, we assume that the background populations for both procedures are identical and that our data represent an unbiased and complete representation of LTx after allo-SCT in this geographically defined area. Also, the available complete data of all LTx performed in other patients of matched age and using the same procedure (BLTx) in the same time period provides valuable control data for comparisons of survival.
It has been a concern that LTx may lead to a relapse of the malignant condition that was treated with allo-SCT. Generally, the International Society for Heart and Lung Transplantation recommends that LTx should not be performed in the first 2 years after malignant disease, and a five-year disease-free interval is considered prudent. 16 Nevertheless, successful LTx after allo-SCT has been performed o5 years after leukemia treated by allo-SCT, 15 and it has been speculated that the cGVHD in these patients may reduce the risk of recurrence. 4 In our patients, there was a long mean interval between allo-SCT and LTx, but two patients were transplanted o2 years and five o5 years after allo-SCT. It is noteworthy that the patient in our report who died of relapsing AML had an interval of only 13 months between allo-SCT and LTx. Additionally, although the causal relationship is not clear, it is conceivable that the rejection episode and its intensively immunosuppressive treatment may have contributed to the occurrence of the aggressive relapse 4 weeks later, due to loss of a putative graft versus leukemia effect. Apart from the time factor, the underlying AML may be considered to be a more aggressive disease, which also may be less susceptible to the GVL effect than CML. 17 However, a relapse has not been observed in any of the other patients with AML in our study despite a long total observation time. Our observations do not allow any conclusions, but show that relapse of malignant disease after LTx is not common. This is in accordance with the observations reported by Koenecke et al., 15 who found that only two patients (5%) receiving any solid organ transplant had a relapse of the underlying malignant disease. Moreover, in the study by Chiang and Lazarus 13 (n ¼ 8), none had such a relapse. In summary, recurrence of malignant disease seems to be rare. Although there may be a higher risk when there is a short interval between allo-SCT and LTx, we observed no predictable relationship between the underlying disease and the risk of recurrence.
Another concern when evaluating these patients for LTx is the increased risk of infection. First, although allo-SCT patients are already at increased risk of CMV infections, this was not a major problem in our recipients and is comparable to earlier reports. 15 This indicates that although CMV infection is an important problem after LTx, it does not seem to be more common in patients who have LTx due to cGVHD/BOS than in other lung-transplanted patients. 18 Second, many patients with cGVHD have affected mucosal barriers and some have hypogammaglobulinemia leading to increased susceptibility to encapsulated bacteria. Consequently, some are colonized with microbes that are known to be problematic in LTx, specifically fungi such as Aspergillus spp., or microbes with reduced susceptibility to antimicrobial treatment, such as Pseudomonas spp. 19 Although colonization with Pseudomonas spp. may be acceptable for LTx, the presence of molds such as Aspergillus spp. may be considered a relative contraindication for LTx in many centers. The observation that one of our patients died from septicemia and multiorgan failure 2 months after LTx may possibly indicate colonization or infection acquired before LTx despite a thorough pretransplant evaluation without any such signs. In contrast, two patients who had been colonized with notoriously problematic microbes, such as P. aeruginosa and S. maltophilia, had an uncomplicated course after LTx.
Generally, it is required that patients should have a potential for rehabilitation to be accepted for LTx. In practice, this may simply be tested in the six-minute walk test, where a walking distance of at least 150-200 m or an equivalent achievement may be required. Although most patients in this study met such requirements, there was no systematic pre-LTx rehabilitation program. Notably, although many patients with severe respiratory insufficiency show signs of malnourishment, the patient who died from septicemia in our study (no. 11 in Table 2 ) was particularly affected, and it is likely that this may have contributed to the fatal outcome. In addition, in LTx recipients, using high doses of corticosteroids is considered a risk factor, and weaning to doses less than the equivalent of 10 mg prednisolone daily is usually recommended, and while calcineurin inhibitors and drugs such as azathioprine and mycophenolate are usually continued, other immunosuppressants are usually weaned before LTx. The high doses of steroids required in this patient may have been an indication of a poor prognosis after LTx.
An age over 65 years is considered a relative contraindication for LTx, although the absolute age limit may vary between different LTx-centers. It is known however that high age is a negative predictive factor. 14 Although no particular age limit for LTx has been agreed for the allo-SCT patients, it seems clear that younger patients have been selected in this study, presumably to minimize known risk factors in a group of patients with uncertain prognosis. Although this study allows no conclusions regarding what upper age limit should be recommended for LTx in allo-SCT patients, this is certainly a question that should be addressed in future prospective studies.
All 13 patients received BLTx. Although only two patients were known to have airways colonized with problematic microbes, obliterative bronchiolitis is frequently associated with mucus retention, in which case a SLTx would be contraindicated. Again, however, as BLTx has been noted to have better long-term results than SLTx, this choice may also in some cases have been done to reduce known risk factors in patients with an uncertain prognosis.
Finally, given the prevailing shortage of organs available for LTx, the accumulated evaluation of possible risk and potential benefit of LTx after allo-SCT must be compared with risk and benefit in other patient groups for whom LTx is the only effective treatment. The most important limitation for long-term survival after LTx is BOS, normally affecting 30-50%.
14 About a third of our patients developed BOS, of whom one received a successful re-LTx. Thus, in this study, BOS is not more common in patients lung transplanted after allo-SCT than in other lung transplanted patients. Furthermore, survival in our patients was not inferior to matched LTx patients from Scandiatransplant in the same time period. On the contrary, the survival seems to be better in the allo-SCT-patients than in the matched LTx patients, but as our material is small and the observation time is short in some, the figures must be interpreted cautiously. Notably, however, the matched group had a better survival than the total number of lung transplanted patients in the same time period. This is not surprising, as it has been shown that long-term survival is better after BLTx compared with single LTx, and better in younger than older patients.
14 Thus, we assume that LTx after allo-SCT has a prognosis not inferior to other LTx, keeping in mind that these patients were younger than the general LTx population, and that all received BLTx.
CONCLUSION
This study indicates that LTx may be a feasible option for patients with BOS due to cGVHD after allo-SCT, and that the long-term results are not inferior to the general LTx population. Given the increasing rate of allo-SCT and the increasing numbers of long-term survivors, GVHD/BOS will be an increasing problem. It may therefore be expected that the number of such patients referred to evaluation for LTx will increase. Future studies should determine the optimal selection of patients, keeping in mind both the optimization of each individual patient's prognosis and the optimal utilization of the limited number of available lung allografts.
